Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
arisen that exhibit increased viral transmissibility and partial evasion of immunity induced by …

Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines show
protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the …

The emergence of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern threatens the efficacy of currently approved vaccines and authorized …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
of concern threatens the efficacy of existing vaccines and therapeutic antibodies and …

Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) can transmit more efficiently and partially evade protective immune …

Many SARS-CoV-2 variants have mutations at key sites targeted by antibodies. However, it
is unknown if antibodies elicited by infection with these variants target the same or different …

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

The increasing prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) variants with spike protein mutations raises concerns that antibodies elicited by natural …

The continuous emergence of new variants of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has made it challenging to develop broad-spectrum …